Poster & Publications

Advances in Liquid Biopsy for Glioblastoma Diagnosis and Monitoring through Nucleosome Epigenetic Modifications Tracking

May 08, 2025

Share
Tweet
Share on Facebook
Share

Paper titled: Advances in Liquid Biopsy for Glioblastoma Diagnosis and Monitoring through Nucleosome Epigenetic Modifications Tracking

Priscilla Van den Ackerveken, Jonathan Decarpentrie, Clotilde Hannart, Nathalie Hardat, Matteo Riva, Nathalie Donis, Fabienne George, Lionel d’Hondt, Jonathan Douxilfs, Marielle Herzog

Presented at ISMRC 2025

Download

Media & Downloads
Nu.Q® Immunoassay enables fast and reproducible monitoring of EZH2 inhibitor performance
Poster & Publications
Liquid biopsy: measuring circulating H3K27Me3-nucleosomes in Lung Cancer patients is a strong prognostic biomarker and a potential aid in treatment selection

Share
Tweet
Share on Facebook
Share

Subscribe for Volition product updates.

Or, click here for Investor Updates and press releases.

"*" indicates required fields

Advances in Liquid Biopsy for Glioblastoma Diagnosis and Monitoring through Nucleosome Epigenetic Modifications Tracking

Related Articles

Nu.Q® Immunoassay enables fast and reproducible monitoring of EZH2 inhibitor performance

Liquid biopsy: measuring circulating H3K27Me3-nucleosomes in Lung Cancer patients is a strong prognostic biomarker and a potential aid in treatment selection

Subscribe for Volition product updates.

Or, click here for Investor Updates and press releases.

Contact